Viking Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Viking Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. 

CEO
Brian Lian
CEOBrian Lian
Employees
53
Employees53
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2012
Founded2012
Employees
53
Employees53

VKTX Key Statistics

Market cap
3.56B
Market cap3.56B
Price-Earnings ratio
-7.52
Price-Earnings ratio-7.52
Dividend yield
Dividend yield
Average volume
2.67M
Average volume2.67M
High today
$32.00
High today$32.00
Low today
$30.30
Low today$30.30
Open price
$31.37
Open price$31.37
Volume
720.70K
Volume720.70K
52 Week high
$43.15
52 Week high$43.15
52 Week low
$22.96
52 Week low$22.96

Stock Snapshot

With a market cap of 3.56B, Viking Therapeutics(VKTX) trades at $30.74. The stock has a price-to-earnings ratio of -7.52.

During the trading session on 2026-05-01, Viking Therapeutics(VKTX) shares reached a daily high of $32.00 and a low of $30.30. At a current price of $30.74, the stock is +1.5% higher than the low and still -3.9% under the high.

Trading activity shows a volume of 720.7K, compared to an average daily volume of 2.67M.

Over the past 52 weeks, Viking Therapeutics(VKTX) stock has traded between a high of $43.15 and a low of $22.96.

Over the past 52 weeks, Viking Therapeutics(VKTX) stock has traded between a high of $43.15 and a low of $22.96.

VKTX News

Simply Wall St 1d
Viking Therapeutics Is Down 8.5% After Wider Q1 Loss And VANQUISH-2 Enrollment Completion - Has The Bull Case Changed?

Viking Therapeutics has reported Q1 2026 results, with a net loss of US$158.33 million and basic and diluted loss per share of US$1.37, while also completing pa...

Viking Therapeutics Is Down 8.5% After Wider Q1 Loss And VANQUISH-2 Enrollment Completion - Has The Bull Case Changed?
TipRanks 2d
Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)

Cash, cash equivalents and short-term investments at quarter end were $603M vs. $706M at previous quarter end. “We are excited to report that the advances and s...

Analyst ratings

89%

of 19 ratings
Buy
89.5%
Hold
10.5%
Sell
0%

People also own

Based on the portfolios of people who own VKTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.